Marker Therapeutics (MRKR) Total Debt (2010 - 2022)

Marker Therapeutics (MRKR) posted quarterly Total Debt of $2.5 million for Q4 2022, down 50.5% quarter-over-quarter from $5.0 million in Q3 2022.

Marker Therapeutics (MRKR) Total Debt (2010 - 2022) Analysis & Trends

Marker Therapeutics (MRKR) has reported Total Debt for 7 consecutive years, with $2.5 million the latest figure, recorded in Q4 2022.

In Q4 2022, Total Debt changed N/A year-over-year to $2.5 million; the TTM figure through Dec 2022 stood at $2.5 million (changed N/A YoY), while the FY2022 annual figure was $2.5 million, changed N/A from the prior year.
Total Debt eased to $2.5 million in Q4 2022 per MRKR's latest filing, from $5.0 million in the prior quarter.
Across five years, Total Debt topped out at $8.0 million in Q2 2022 and bottomed at $2.5 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	Marker Therapeutics	23.95 Mn	12.02 Mn	-	-

Download Data